Literature DB >> 7008048

Efficacy of nifedipine in the treatment of angina pectoris and chronic airways obstruction.

S S Jaiprakash, J N Sahay, S S Chatterjee, G MacDonald.   

Abstract

Twenty patients suffering from angina pectoris with co-existing fixed or labile airways obstruction, were administered fortnightly treatment periods of nifedipine or matching placebo over an 8-week period. Maintenance treatment for their airways obstruction continued throughout this period. Nifedipine was found to be an effective drug in controlling their angina, and did not have an adverse effect on the airways obstruction. Both systolic and diastolic BP was reduced over a 90-min period after administration of a single dose of nifedipine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7008048      PMCID: PMC2425946          DOI: 10.1136/pgmj.56.659.624

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  15 in total

1.  Comparison of effects of metoprolol and propranolol on asthmatic airway obstruction.

Authors:  C Skinner; J Gaddie; K N Palmer
Journal:  Br Med J       Date:  1976-02-28

2.  Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis.

Authors:  D J Sinclair
Journal:  Br Med J       Date:  1979-01-20

3.  Acute and chronic effects of nifedipine in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

4.  [Clinical and experimental studies on the efficiency of nifedipine on smooth muscle strips of the esophagus (author's transl)].

Authors:  H F Weiser; G Lepsien; K Golenhofen; G Schattenmann; R Siewert
Journal:  Z Gastroenterol       Date:  1977-11       Impact factor: 2.000

5.  Haemodynamic effects of a calcium antagonistic agent (nifedipine) in hypertension: therapeutic implications.

Authors:  C Bartorelli; F Magrini; P Moruzzi; M T Olivari; A Polese; C Fiorentini; M Guazzi
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

6.  Therapeutic effects of pindolol and nifedipine in patients with stable angina pectoris and asymptomatic resting ischemia.

Authors:  G Cocco; C Strozzi; D Chu; R Amrein; E Castagnoli
Journal:  Eur J Cardiol       Date:  1979-07

7.  Effects of muliple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease.

Authors:  L Tivenius
Journal:  Scand J Respir Dis       Date:  1976

8.  Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo.

Authors:  A Forman; K E Andersson; L Henriksson; T Rud; U Ulmsten
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-08

9.  Inhibition of prostaglandin-induced uterine activity by nifedipine.

Authors:  K E Andersson; I Ingemarsson; U Ulmsten; L Wingerup
Journal:  Br J Obstet Gynaecol       Date:  1979-03

10.  Relaxing effects of Nifedipine on the nonpregnant human uterus in vitro and in vivo.

Authors:  U Ulmsten; K E Andersson; A Forman
Journal:  Obstet Gynecol       Date:  1978-10       Impact factor: 7.661

View more
  5 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Calcium channel blockers and asthma.

Authors:  S Y So; M Ip; W K Lam
Journal:  Lung       Date:  1986       Impact factor: 2.584

3.  Calcium-channel blockers and asthma.

Authors:  P J Barnes
Journal:  Thorax       Date:  1983-07       Impact factor: 9.139

4.  Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma.

Authors:  D O Williams; P J Barnes; H P Vickers; M Rudolf
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-01

5.  A calcium antagonist, nifedipine, modifies exercise-induced asthma.

Authors:  P J Barnes; N M Wilson; M J Brown
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.